Veracyte, Inc.

218 articles with Veracyte, Inc.

• Veracyte Announces Sponsorship of the Climb to Fight Cancer’s Team Kilimanjaro Expedition

  3/19/2019

  Veracyte, Inc. (Nasdaq: VCYT), a leading genomics diagnostics company, today announced its “Summit” level sponsorship of the Climb to Fight Cancer’s Team Kilimanjaro expedition as part of the company’s expanded efforts to combat this disease.

• Veracyte Announces New Afirma Xpression Atlas Data on Medullary Thyroid Cancer to Be Presented at ENDO 2019

  3/18/2019

  Veracyte, Inc. announced that new data derived from the Afirma® Xpression Atlas, which help characterize the genomic underpinning of medullary thyroid cancer, will be presented at ENDO 2019, the Endocrine Society’s annual meeting.

• Veracyte Receives Final Medicare Coverage Policy for Envisia Genomic Classifier

  3/4/2019

  Genomic Test is the First to Be Granted Medicare Coverage for Improved Diagnosis of Idiopathic Pulmonary Fibrosis

• Veracyte Announces Fourth Quarter and Full-Year 2018 Financial Results and Provides 2019 Financial Outlook

  2/25/2019

  Veracyte, Inc. announced financial results and business progress for the quarter and full year ended December 31, 2018, and provided financial guidance for 2019.

• Veracyte Announces Participation in Upcoming Investor Conferences

  2/20/2019

  Veracyte, Inc. announced that members of its management team will be participating in two upcoming investor conferences.

• Veracyte to Release Fourth Quarter and Full-Year 2018 Financial Results February 25, 2019

  1/28/2019

  Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the fourth quarter and full-year 2018 after the close of market on Monday, February 25, 2019.

• Veracyte to Present at the 21st Annual Needham Growth Conference

  1/9/2019

  Veracyte, Inc. today announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the 21st Annual Needham Growth Conference in New York City on Tuesday, January 15, 2019 at 8:40 a.m. EST (5:40 a.m. PST).

• 

  Let's Make a Deal: Veracyte & J&J, Vertex & Arbor, Esperion & Daiichi Sankyo and More

  1/4/2019

  With the holidays over and the JP Morgan Healthcare Conference next week, companies were clearly revving their engines, ready to race into the new year. Here’s a roundup of some of the top deals that were announced today.

• Veracyte Announces Strategic Collaboration with Johnson & Johnson Innovation in Battle Against Lung Cancer

  1/3/2019

  Veracyte, Inc. (“Veracyte”) (Nasdaq: VCYT) announced today that it has entered into a long-term strategic collaboration with Johnson & Johnson Innovation LLC* and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable.

• Veracyte to Present at the 37th Annual J.P. Morgan Healthcare Conference

  1/2/2019

  Veracyte, Inc. today announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 11:30 a.m. PST (2:30 p.m. EST) followed by a question and answer (Q&A) session at 12:00 p.m. PST (3:00 p.m. EST).

• Veracyte Announces Expansion of Envisia Genomic Classifier Early Access Program

  12/5/2018

  Veracyte, Inc. (Nasdaq: VCYT) today announced that 20 medical centers across the United States are now offering the Envisia Genomic Classifier through an Early Access Program (EAP) to patients who are undergoing evaluation for interstitial lung diseases (ILD), including idiopathic pulmonary fibrosis (IPF

• Veracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

  11/9/2018

  Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018, at 9:00 a.m. Eastern Time (ET).

• Veracyte Announces Publication of Data Demonstrating “Real World” Performance of Afirma GSC in Thyroid Cancer Diagnosis

  11/8/2018

  Veracyte, Inc. announced today the publication of “real world” data showing that the Afirma® Genomic Sequencing Classifier (GSC) enables even more patients to avoid unnecessary surgery in thyroid cancer diagnosis compared to the company’s flagship, original Afirma Gene Expression Classifier (GEC). The findings are published online in Endocrine Practice, the journal of the American Association of Clinical Endocrinologists.

• Veracyte Announces Third Quarter 2018 Financial Results

  10/29/2018

  Revenue Grew 34 Percent and Genomic Test Volume Increased 23 Percent

• Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results on Monday, October 29, 2018

  10/15/2018

  Veracyte, Inc. (Nasdaq: VCYT) will release its third quarter 2018 financial results after the close of market on Monday, October 29, 2018

• Veracyte Announces Presentation of “Real World” Clinical Utility Data at CHEST 2018 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis

  10/9/2018

  Preliminary data from ongoing, three-year registry study demonstrate that reduction in potentially harmful invasive procedures extends for first 12 months post-test

• Veracyte Announces Presentation of Data Confirming Envisia Genomic Classifier’s Ability to Improve Diagnosis of Idiopathic Pulmonary Fibrosis

  10/8/2018

  Veracyte, Inc. (Nasdaq: VCYT) announced the presentation of data demonstrating that the Envisia Genomic Classifier can help physicians more confidently diagnose interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), without the need for surgery.

• Veracyte Announces that New Data from Multiple Studies Demonstrate “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis

  10/6/2018

  Study findings reported at the American Thyroid Association Annual Meeting

• Veracyte to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

  9/27/2018

  Veracyte, Inc. today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018, at 1:05 p.m. Eastern Time (ET).

• Veracyte Announces Multiple Studies to Be Presented at ATA Annual Meeting Demonstrating “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis

  9/26/2018

  Veracyte Announces Multiple Studies to Be Presented at ATA Annual Meeting Demonstrating “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis